Concert Pharma (CNCE) – Business Wire
-
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
-
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
-
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
-
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
-
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
-
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
-
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
-
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
-
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
-
Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
-
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
-
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
-
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
-
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
-
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
-
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
-
Concert Pharmaceuticals Announces Pricing of Public Offering
-
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
-
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
-
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
-
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
-
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
-
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
-
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
-
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
-
Concert Pharmaceuticals Announces $65 Million Financing
-
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
-
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
-
Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month
-
Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
-
Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021
-
Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
-
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
-
Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
-
Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021
-
KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
-
Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
-
Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
-
Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
Back to CNCE Stock Lookup
